We assign a fundamental rating of 3 out of 10 to NKTX. NKTX was compared to 524 industry peers in the Biotechnology industry. NKTX has a great financial health rating, but its profitability evaluates not so good. NKTX has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.02% | ||
| ROE | -30.37% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.16 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.23 | ||
| Quick Ratio | 15.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 3 / 10 to NKTX.
ChartMill assigns a valuation rating of 0 / 10 to NKARTA INC (NKTX). This can be considered as Overvalued.
NKARTA INC (NKTX) has a profitability rating of 1 / 10.